Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jun;13 Suppl 1(0 1):S151-60.
doi: 10.1111/jth.12957.

Gene therapy in an era of emerging treatment options for hemophilia B

P E Monahan  1   2   3
Affiliations
Review

Gene therapy in an era of emerging treatment options for hemophilia B

P E Monahan. J Thromb Haemost. 2015 Jun.

Abstract

Factor IX deficiency (hemophilia B) is less common than factor VIII deficiency (hemophilia A), and innovations in therapy for hemophilia B have generally lagged behind those for hemophilia A. Recently, the first sustained correction of the hemophilia bleeding phenotype by clotting factor gene therapy has been described using recombinant adeno-associated virus (AAV) to deliver factor IX. Despite this success, many individuals with hemophilia B, including children, men with active hepatitis, and individuals who have pre-existing natural immunity to AAV, are not eligible for the current iteration of hemophilia B gene therapy. In addition, recent advances in recombinant factor IX protein engineering have led some hemophilia treaters to reconsider the urgency of genetic cure. Current clinical and preclinical approaches to advancing AAV-based and alternative approaches to factor IX gene therapy are considered in the context of current demographics and treatment of the hemophilia B population.

Keywords: clinical trial; dependovirus; factor IX; genetic therapy; hemophilia B.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, O’Beirne J, Smith K, Pasi J, Glader B, Rustagi P, Ng CY, Kay MA, Zhou J, Spence Y, Morton CL, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia b. N Engl J Med. 2011;365:2357–65. - PMC - PubMed
    1. Shapiro AD, Ragni MV, Valentino LA, Key NS, Josephson NC, Powell JS, Cheng G, Thompson AR, Goyal J, Tubridy KL, Peters RT, Dumont JA, Euwart D, Li L, Hallen B, Gozzi P, Bitonti AJ, Jiang H, Luk A, Pierce GF. Recombinant factor ix-fc fusion protein (rfixfc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia b patients. Blood. 2013;119:666–72. - PMC - PubMed
    1. Kaufman RJ, Powell JS. Molecular approaches for improved clotting factors for hemophilia. Blood. 2013;122:3568–74. - PMC - PubMed
    1. Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, Della Peruta M, Lheriteau E, Patel N, Raj D, Riddell A, Pie J, Rangarajan S, Bevan D, Recht M, Shen YM, Halka KG, Basner-Tschakarjan E, Mingozzi F, High KA, et al. Long-term safety and efficacy of factor ix gene therapy in hemophilia b. N Engl J Med. 2014;371:1994–2004. - PMC - PubMed
    1. Calcedo R, Morizono H, Wang L, McCarter R, He J, Jones D, Batshaw ML, Wilson JM. Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin Vaccine Immunol. 2011;18:1586–8. - PMC - PubMed

Publication types